• Considering whether Zai Lab at US$20.75 is starting to look like value after a rough few years, or whether the risks still outweigh the potential upside.
• The share price has been volatile recently, with a 9.3% decline over the last 7 days, a 16.2% gain over the past month, and a 19.7% return year to date. The 1 year return sits at a 34.5% decline and the 5 year return at an 86.3% decline.
• Recent price moves sit against a backdrop of ongoing interest in biotech names, regulatory developments, and shifting sentiment around drug pipelines and partnerships. For Zai Lab, this mix of sector noise and company specific expectations has kept investors focused on what the current share price might already be factoring in.
• Zai Lab currently has a valuation score of 4 out of 6. This means several checks suggest the shares may be priced below some estimates of fair value, while others do not. Next, it is worth walking through the key valuation approaches behind that score, and then looking at an even richer way to think about value that will come at the end of this article.

Approach 1: Zai Lab Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future cash flows and then discounting those back to today’s value.

For Zai Lab, the latest twelve month free cash flow is a loss of $179.2 million. Analysts and model projections expect free cash flow to remain negative for several years, with an estimated $135.98 million outflow in 2026 and $94.53 million in 2027, before moving into positive territory by 2029. By 2030, the projection in this model reaches $181.97 million in free cash flow, all expressed in US$.

The DCF here uses a 2 Stage Free Cash Flow to Equity approach, combining these multi year forecasts with a longer term extrapolation. In this model, that produces an estimated intrinsic value of $76.99 per share. When compared with the current share price of $20.75, this implies the shares trade at a 73.0% discount to that DCF estimate. On this model alone, the stock appears undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Zai Lab is undervalued by 73.0%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

Approach 2: Zai Lab Price vs Sales

For companies where earnings are not yet positive, the P/S ratio is often a useful cross check because it compares what investors are paying to the revenue actually being generated.

Growth expectations and risk still matter here, because higher growth and lower perceived risk can justify a higher P/S multiple, while slower growth or higher uncertainty tend to support a lower "normal" range.

Zai Lab currently trades on a P/S ratio of 5.07x. This sits below the Biotechs industry average of 10.82x and also below the peer group average of 7.32x. On simple comparisons, that points to a lower revenue multiple than many similar names.

Simply Wall St’s Fair Ratio is designed to go a step further. It estimates what the preferred multiple might be given factors such as earnings growth, industry, profit margins, market cap and the company’s risk profile, rather than only lining it up against peers.

For Zai Lab, the Fair Ratio is 3.07x, which is below the current 5.07x P/S ratio. That gap suggests the shares are pricing in more than the Fair Ratio implies.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Zai Lab Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as a simple way for you to attach a clear story about Zai Lab to the numbers you see, linking your view of its drug pipeline, China exposure and competition to a financial forecast and a Fair Value. This can then be compared directly with the current share price to help you decide whether the gap looks large enough to act. All of this is available within Simply Wall St’s Community page, where Narratives update automatically as new news or earnings arrive. For example, one Zai Lab Narrative might lean cautious with a Fair Value around US$21.80, while another sees more upside at US$55.00. This shows how different but transparent assumptions can coexist side by side.

Do you think there's more to the story for Zai Lab? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.